The primary goal of the PPTC is to identify new agents that have the potential for significant activity when clinically evaluated against selected childhood cancers.
The Pediatric Preclinical Testing Consortium (PPTC) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PPTC is supported through an NCI research contract to The Research Institute at Nationwide Children’s Hospital with Dr. Peter Houghton as the Principal Investigator. Testing occurs at The Research Institute and subcontract sites with expertise in specific childhood cancers.
The consortium is based on a substantial body of data showing that appropriate childhood cancer preclinical in vivo models can recapitulate known effective agents’ anti-tumor activity and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating the development of a more reliable pediatric new agent prioritization process, the Pediatric Preclinical Testing Consortium will contribute to the goal of identifying more effective treatments for children with cancer.
PPTP Principal Investigators
- Dr. Peter Houghton, Ph.D.
Greehey Children’s Cancer Research Institute
- Dr. E. Anders Kolb, M.D.
A. I DuPont Children’s Hospital, Wilmington
- Dr. Richard Gorlick, M.D.
Children’s Hospital at Montefiore, Albert Einstein College of Medicine
- Dr. Stephen Keir, Ph.D.
Preston Robert Tisch Brain Tumor Center, Duke University
- Dr. John Maris, M.D.
Children’s Hospital of Philadelphia
- Dr. Richard Lock, Ph.D.
Children’s Cancer Institute, Randwick, Australia
- Dr. C. Patrick Reynolds, M.D., Ph.D.
Texas Tech University Health Science Center, Lubbock
Raushan T. Kurmasheva, Ph.D.
PPTP Program Manager
Greehey Children’s Cancer Research Institute,
UT Health San Antonio
8403 Floyd Curl Dr. Mail Code 7784
San Antonio, Texas 78229